Day One Biopharmaceuticals (DAWN)
(Delayed Data from NSDQ)
$15.97 USD
-0.20 (-1.24%)
Updated May 20, 2024 04:00 PM ET
After-Market: $16.01 +0.04 (0.25%) 6:40 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DAWN 15.97 -0.20(-1.24%)
Will DAWN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for DAWN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DAWN
Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More
Here's What Could Help Day One Biopharmaceuticals, Inc. (DAWN) Maintain Its Recent Price Strength
DAWN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Day One Biopharmaceuticals, Inc. (DAWN) Could Surge 85%: Read This Before Placing a Bet
Biotech ETF Tops in June: 5 Stocks That Outperform
Other News for DAWN
BrightSpring Health announces Onco360 selected as partner for OJEMDA
Bank of America Securities Reaffirms Their Sell Rating on Day One Biopharmaceuticals (DAWN)
Analysts’ Top Healthcare Picks: Viridian Therapeutics (VRDN), Day One Biopharmaceuticals (DAWN)
Buy Rating for Day One Biopharmaceuticals Amidst DAY101 Approval and Strong Market Entry
Buy Rating on Day One Biopharmaceuticals: Ojemda’s Market Potential and Strategic Commercialization